{"DataElement":{"publicId":"8067190","version":"1","preferredName":"Anticoagulant Agent Administered Type","preferredDefinition":"The type of anticoagulant administered to the patient","longName":"ANT_COAG_ADM_TYP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"2014209","version":"1","preferredName":"Anticoagulant Agent Administered","preferredDefinition":"the administration of anticoagulant to the patient.","longName":"ACOAG_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2184079","version":"1","preferredName":"Anticoagulant Agent","preferredDefinition":"A drug that helps prevent blood clots from forming. Also called a blood thinner.","longName":"Anticoagulant Agent","context":"TEST","contextVersion":"1","Concepts":[{"longName":"Anticoagulant Agent","conceptCode":"C263","definition":"Any agent capable of preventing blood clot formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB67BCB3-50E0-6E9A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"BMCCURRY","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B67A9228-B532-053B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-12","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-02-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"ISO 11179 compliance.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"8067185","version":"1","preferredName":"Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"8067185v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"ALPHANUMERIC","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"6431768","version":"1","preferredName":"Other","longName":"6431768v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"762A692A-EEF7-29A1-E053-F662850A9EA9","latestVersionIndicator":"Yes","beginDate":"2018-09-18","endDate":null,"createdBy":"WINCHC","dateCreated":"2018-09-18","modifiedBy":"GDEEN","dateModified":"2024-01-22","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9314D69-3889-1A8F-E053-4EBD850ABAEA","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"ONEDATA","dateModified":"2022-03-01","deletedIndicator":"No"},{"value":"Fondaparinux","valueDescription":"fondaparinux","ValueMeaning":{"publicId":"2577874","version":"1","preferredName":"fondaparinux","longName":"2577874v1.00","preferredDefinition":"A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fondaparinux","conceptCode":"C73142","definition":"A synthetic glucopyranoside with antithrombotic activity. Fondaparinux selectively binds to antithrombin III, thereby potentiating the innate neutralization of activated factor X (Factor Xa) by antithrombin. Neutralization of Factor Xa inhibits its activity and interrupts the blood coagulation cascade, thereby preventing thrombin formation and thrombus development.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD3F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9314D69-3893-1A8F-E053-4EBD850ABAEA","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"ONEDATA","dateModified":"2022-03-01","deletedIndicator":"No"},{"value":"Direct factor Xa inhibitors (e.g., apixaban)","valueDescription":"Direct factor Xa inhibitors (e.g., apixaban)","ValueMeaning":{"publicId":"8067186","version":"1","preferredName":"Direct factor Xa inhibitors (e.g., apixaban)","longName":"8067186v1.00","preferredDefinition":"Any agent that binds to and inactivates factor Xa, with anticoagulant activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Direct Factor Xa Inhibitor","conceptCode":"C173067","definition":"Any agent that binds to and inactivates factor Xa, with anticoagulant activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9314D69-389D-1A8F-E053-4EBD850ABAEA","latestVersionIndicator":"Yes","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9314D69-38B6-1A8F-E053-4EBD850ABAEA","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"ONEDATA","dateModified":"2022-03-01","deletedIndicator":"No"},{"value":"Direct thrombin inhibitors (e.g., argatroban)","valueDescription":"Direct thrombin inhibitors (e.g., argatroban)","ValueMeaning":{"publicId":"8067187","version":"1","preferredName":"Direct thrombin inhibitors (e.g., argatroban)","longName":"8067187v1.00","preferredDefinition":"Any agent that directly binds to and inactivates thrombin (factor IIa), with anticoagulant activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Direct Thrombin Inhibitor","conceptCode":"C173066","definition":"Any agent that directly binds to and inactivates thrombin (factor IIa), with anticoagulant activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9314D69-38C0-1A8F-E053-4EBD850ABAEA","latestVersionIndicator":"Yes","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9314D69-38D9-1A8F-E053-4EBD850ABAEA","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"ONEDATA","dateModified":"2022-03-01","deletedIndicator":"No"},{"value":"Unfractionated heparin","valueDescription":"Heparin","ValueMeaning":{"publicId":"2567254","version":"1","preferredName":"Heparin","longName":"2567254","preferredDefinition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heparin","conceptCode":"C539","definition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D3C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9314D69-38E3-1A8F-E053-4EBD850ABAEA","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"ONEDATA","dateModified":"2022-03-01","deletedIndicator":"No"},{"value":"Low-molecular weight heparin (LMWH)","valueDescription":"Low-molecular weight heparin (LMWH)","ValueMeaning":{"publicId":"8067188","version":"1","preferredName":"Low-molecular weight heparin (LMWH)","longName":"8067188v1.00","preferredDefinition":"Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Molecular Weight Heparin","conceptCode":"C2578","definition":"Substances comprised of fragmented heparin molecules derived from unfractionated heparin that bind to antithrombin III with a molecular weight ranging from 1000 to 10,000 daltons, which causes changes in property from unfractionated heparin, including decreased protein binding, enhanced bioavailability, decreased platelet interaction, and decreased binding to thrombin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9314D69-38ED-1A8F-E053-4EBD850ABAEA","latestVersionIndicator":"Yes","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9314D69-3906-1A8F-E053-4EBD850ABAEA","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"ONEDATA","dateModified":"2022-03-01","deletedIndicator":"No"},{"value":"Vitamin K antagonists (e.g., warfarin)","valueDescription":"Vitamin K antagonists (e.g., warfarin)","ValueMeaning":{"publicId":"8067189","version":"1","preferredName":"Vitamin K antagonists (e.g., warfarin)","longName":"8067189v1.00","preferredDefinition":"Any agent that inhibits the function of vitamin K, with anticoagulant activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vitamin K Antagonist","conceptCode":"C173064","definition":"Any agent that inhibits the function of vitamin K, with anticoagulant activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9314D69-3910-1A8F-E053-4EBD850ABAEA","latestVersionIndicator":"Yes","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D9314D69-3929-1A8F-E053-4EBD850ABAEA","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"ONEDATA","dateModified":"2022-03-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9314D69-3874-1A8F-E053-4EBD850ABAEA","latestVersionIndicator":"Yes","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-09-20","changeDescription":null,"administrativeNotes":"2023.9.20 Updated def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Which of the following was re","type":"Preferred Question Text","description":"Which of the following was received?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9314D69-3939-1A8F-E053-4EBD850ABAEA","latestVersionIndicator":"Yes","beginDate":"2022-03-01","endDate":null,"createdBy":"COOPERJ","dateCreated":"2022-03-01","modifiedBy":"COOPERJ","dateModified":"2022-03-01","changeDescription":"Created for ACCL21C2. -JC 3/1/2022","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}